KEGG   DRUG: Albutrepenonacog alfa
Entry
D10770                      Drug                                   
Name
Albutrepenonacog alfa (INN);
Albutrepenonacog alfa (genetical recombination) (JAN);
Idelvion (TN)
Sequence
YNSGKLEEFV QGNLERECME EKCSFEEARE VFENTERTTE FWKQYVDGDQ CESNPCLNGG
SCKDDINSYE CWCPFGFEGK NCELDVTCNI KNGRCEQFCK NSADNKVVCS CTEGYRLAEN
QKSCEPAVPF PCGRVSVSQT SKLTRAETVF PDVDYVNSTE AETILDNITQ STQSFNDFTR
VVGGEDAKPG QFPWQVVLNG KVDAFCGGSI VNEKWIVTAA HCVETGVKIT VVAGEHNIEE
TEHTEQKRNV IRIIPHHNYN AAINKYNHDI ALLELDEPLV LNSYVTPICI ADKEYTNIFL
KFGSGYVSGW GRVFHKGRSA LVLQYLRVPL VDRATCLRST KFTIYNNMFC AGFHEGGRDS
CQGDSGGPHV TEVEGTSFLT GIISWGEECA MKGKYGIYTK VSRYVNWIKE KTKLTPVSQT
SKLTRAETVF PDVDAHKSEV AHRFKDLGEE NFKALVLIAF AQYLQQCPFE DHVKLVNEVT
EFAKTCVADE SAENCDKSLH TLFGDKLCTV ATLRETYGEM ADCCAKQEPE RNECFLQHKD
DNPNLPRLVR PEVDVMCTAF HDNEETFLKK YLYEIARRHP YFYAPELLFF AKRYKAAFTE
CCQAADKAAC LLPKLDELRD EGKASSAKQR LKCASLQKFG ERAFKAWAVA RLSQRFPKAE
FAEVSKLVTD LTKVHTECCH GDLLECADDR ADLAKYICEN QDSISSKLKE CCEKPLLEKS
HCIAEVENDE MPADLPSLAA DFVESKDVCK NYAEAKDVFL GMFLYEYARR HPDYSVVLLL
RLAKTYETTL EKCCAAADPH ECYAKVFDEF KPLVEEPQNL IKQNCELFEQ LGEYKFQNAL
LVRYTKKVPQ VSTPTLVEVS RNLGKVGSKC CKHPEAKRMP CAEDYLSVVL NQLCVLHEKT
PVSDRVTKCC TESLVNRRPC FSALEVDETY VPKEFNAETF TFHADICTLS EKERQIKKQT
ALVELVKHKP KATKEQLKAV MDDFAAFVEK CCKADDKETC FAEEGKKLVA ASQAALGL
(Disulfide bridge: 18-23, 51-62, 56-71, 73-82, 88-99, 95-109, 111-124, 132-289, 206-222, 336-350, 361-389, 486-495, 508-524, 523-534, 557-602, 601-610, 633-679, 698-712, 711-722, 749-794, 793-802, 825-871, 870-881, 894-910, 909-920, 947-992, 991-1000)
  Type
Peptide
Class
Blood modifier agent
 DG02016  Hemostatics
  DG02014  Blood coagulation accelerant
   DG02013  Blood coagulation factor
Remark
Therapeutic category: 6349
ATC code: B02BD04
Chemical structure group: DG00171
Product (DG00171): D08797<JP/US> D08794<JP> D05201<JP> D10757<JP> D10770<JP>
Efficacy
Bleeding suppressant, Replenisher (coagulation factor)
Target
F9* [HSA_VAR:2158v1] [HSA:2158] [KO:K01321]
  Pathway
hsa04610  Complement and coagulation cascades
  Network
nt06514  Coagulation cascade
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 B BLOOD AND BLOOD FORMING ORGANS
  B02 ANTIHEMORRHAGICS
   B02B VITAMIN K AND OTHER HEMOSTATICS
    B02BD Blood coagulation factors
     B02BD04 Coagulation factor IX
      D10770  Albutrepenonacog alfa (INN) <JP>
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  63  Biological preparations
   634  Human blood preparations
    6349  Others
     D10770  Albutrepenonacog alfa (INN); Albutrepenonacog alfa (genetical recombination) (JAN)
Drug groups [BR:br08330]
 Blood modifier agent
  DG02016  Hemostatics
   DG02014  Blood coagulation accelerant
    DG02013  Blood coagulation factor
     DG00171  Blood coagulation factor IX
      D10770  Albutrepenonacog alfa
Target-based classification of drugs [BR:br08310]
 Peptidases and inhibitors
  Serine peptidases
   Chymotrypsin family
    F9* [HSA_VAR:2158v1]
     D10770  Albutrepenonacog alfa (INN) <JP>
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10770
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D10770
Drug groups [BR:br08330]
 Blood modifier agent
  DG02016  Hemostatics
   DG02014  Blood coagulation accelerant
    DG02013  Blood coagulation factor
     DG00171  Blood coagulation factor IX
Other DBs
CAS: 1357448-54-4
PubChem: 310920488
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system